F
FDA
Guest
The U.S. Food and Drug Administration approved Brixadi (buprenorphine) extended-release injection for subcutaneous use to treat moderate to severe opioid use disorder (OUD)
Baca selengkapnya di : http://www.fda.gov...
Baca selengkapnya di : http://www.fda.gov...